journal article·2017-09-26

Biodegradable Viral Nanoparticle/Polymer Implants Prepared via Melt-Processing

Parker W. Lee, Sourabh Shukla, Jaqueline D. Wallat, Chaitanya Danda, Nicole F. Steinmetz, Joao Maia, Jonathan K. Pokorski

ACS Nano· Volume 11· Issue 9
Publisher page

Abstract

Viral nanoparticles have been utilized as a platform for vaccine development and are a versatile system for the display of antigenic epitopes for a variety of disease states. However, the induction of a clinically relevant immune response often requires multiple injections over an extended period of time, limiting patient compliance. Polymeric systems to deliver proteinaceous materials have been extensively researched to provide sustained release, which would limit administration to a single dose. Melt-processing is an emerging manufacturing method that has been utilized to create polymeric materials laden with proteins as an alternative to typical solvent-based production methods. Melt-processing is advantageous because it is continuous, solvent-free, and 100% of the therapeutic protein is encapsulated. In this study, we utilized melt-encapsulation to fabricate viral nanoparticle laden polymeric materials that effectively deliver intact particles and generate carrier specific antibodies in vivo. The effects of initial processing and postprocessing on particle integrity and aggregation were studied to develop processing windows for scale-up and the creation of more complex materials. The dispersion of particles within the PLGA matrix was studied, and the effect of additives and loading level on the release profile was determined. Overall, melt-encapsulation was found to be an effective method to produce composite materials that can deliver viral nanoparticles over an extended period and elicit an immune response comparable to typical administration schedules.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Protein purification and stability · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Macromolecular Science and Engineering, Case School of Engineering, ‡Department of Biomedical Engineering, Case School of Engineering, §School of Medicine, and ∥Case Comprehensive Cancer Center, Division of General Medical Sciences-Oncology, Case Western Reserve University, Cleveland, Ohio 44106, United States

Funding

National Center for Advancing Translational Sciences · Susan G. Komen for the Cure · Division of Materials Research

References (62)

Show source-provided references
1. 10.1016/S1567-5769(03)00016-X10.1016/S1567-5769(03)00016-X ↗
2. 10.1016/S0264-410X(02)00540-610.1016/S0264-410X(02)00540-6 ↗
3. 10.1038/nmat335510.1038/nmat3355 ↗
4. 10.1002/(SICI)1097-0215(19980911)77:6<901::AID-IJC17>3.0.CO;2-310.1002/(SICI)1097-0215(19980911)77:6<901::AID-IJC17>3.0.CO;2-3 ↗
5. 10.3390/vaccines303066210.3390/vaccines3030662 ↗
6. 10.1111/j.0818-9641.2004.01271.x10.1111/j.0818-9641.2004.01271.x ↗
7. 10.1165/rcmb.2012-0387OC10.1165/rcmb.2012-0387OC ↗
8. 10.2165/00126839-200607040-0000110.2165/00126839-200607040-00001 ↗
9. 10.1002/eji.20073798910.1002/eji.200737989 ↗
10. 10.1016/S0959-440X(96)80072-810.1016/S0959-440X(96)80072-8 ↗
11. 10.1080/21645515.2015.101667510.1080/21645515.2015.1016675 ↗
12. 10.1016/S0969-2126(96)00060-310.1016/S0969-2126(96)00060-3 ↗
13. 10.1021/ja075937f10.1021/ja075937f ↗
14. Huber, A.; Bachmann, M.; Jennings, G.; Tissot, A.; Langedijk, J.; Timmerman, P.; Slootstra, J.; Boshuizen, R.Circular ccr5 Peptide Conjugates and Uses Thereof. Patent CA2672826, June 26, 2008.
15. 10.1021/ja203286n10.1021/ja203286n ↗
16. Bachmann, M.; Fulurija, A.Ghrelin-Carrier Conjugates. Patent US20050191317, September 1, 2005.
17. 10.4049/jimmunol.178.11.745010.4049/jimmunol.178.11.7450 ↗
18. 10.1097/HJH.0b013e32800ff5d610.1097/HJH.0b013e32800ff5d6 ↗
19. 10.1002/cbic.20110046910.1002/cbic.201100469 ↗
20. 10.1021/bi901306p10.1021/bi901306p ↗
21. 10.1021/acschembio.6b0099410.1021/acschembio.6b00994 ↗
22. 10.1038/srep0377510.1038/srep03775 ↗
23. 10.1208/s12248-015-9843-410.1208/s12248-015-9843-4 ↗
24. 10.1016/j.biomaterials.2014.10.05310.1016/j.biomaterials.2014.10.053 ↗
25. 10.1016/j.cellimm.2014.01.00310.1016/j.cellimm.2014.01.003 ↗
26. 10.1007/s11095-009-0045-610.1007/s11095-009-0045-6 ↗
27. 10.1016/S0168-3659(03)00074-910.1016/S0168-3659(03)00074-9 ↗
28. 10.1016/S0939-6411(96)00017-310.1016/S0939-6411(96)00017-3 ↗
29. 10.1016/j.ijpharm.2010.02.02510.1016/j.ijpharm.2010.02.025 ↗
30. 10.1016/j.ijpharm.2011.06.02910.1016/j.ijpharm.2011.06.029 ↗
31. 10.1016/S0168-3659(96)01474-510.1016/S0168-3659(96)01474-5 ↗
32. 10.1016/S0142-9612(00)00115-010.1016/S0142-9612(00)00115-0 ↗
33. 10.1586/erm.09.1510.1586/erm.09.15 ↗
34. 10.1007/s11095-009-0033-x10.1007/s11095-009-0033-x ↗
35. 10.1016/j.ijpharm.2012.09.01510.1016/j.ijpharm.2012.09.015 ↗
36. 10.1016/S0014-5793(01)03284-710.1016/S0014-5793(01)03284-7 ↗
37. 10.1021/jp806762410.1021/jp8067624 ↗
38. 10.1002/mabi.20150014310.1002/mabi.201500143 ↗
39. 10.1208/s12249-016-0548-510.1208/s12249-016-0548-5 ↗
40. 10.1016/j.ejpb.2013.03.03110.1016/j.ejpb.2013.03.031 ↗
41. 10.1016/0032-3861(77)90287-710.1016/0032-3861(77)90287-7 ↗
42. 10.1002/macp.20160001110.1002/macp.201600011 ↗
43. 10.1021/bm200080h10.1021/bm200080h ↗
44. 10.1002/jps.2138610.1002/jps.21386 ↗
45. 10.1002/vnl.730010312.n10.1002/vnl.730010312.n ↗
46. 10.1023/A:100887172038910.1023/A:1008871720389 ↗
47. 10.1002/app.1969.07013021310.1002/app.1969.070130213 ↗
48. 10.1016/j.ejps.2015.11.00510.1016/j.ejps.2015.11.005 ↗
49. 10.1166/jnn.2005.50710.1166/jnn.2005.507 ↗
50. 10.1007/s11095-016-1961-x10.1007/s11095-016-1961-x ↗
51. 10.1134/S1061933X1002019510.1134/S1061933X10020195 ↗
52. 10.1016/S0168-3659(98)00050-910.1016/S0168-3659(98)00050-9 ↗
53. 10.1021/acs.est.5b0464410.1021/acs.est.5b04644 ↗
54. 10.1016/0168-3659(92)90014-I10.1016/0168-3659(92)90014-I ↗
55. 10.1016/j.ijpharm.2007.11.01210.1016/j.ijpharm.2007.11.012 ↗
56. 10.1186/1743-422X-7-14610.1186/1743-422X-7-146 ↗
57. 10.1002/eji.20063665810.1002/eji.200636658 ↗
58. 10.1038/nri220610.1038/nri2206 ↗
59. 10.1186/s40425-014-0029-x10.1186/s40425-014-0029-x ↗
60. 10.3389/fimmu.2015.0036810.3389/fimmu.2015.00368 ↗
61. 10.1038/ncomms549410.1038/ncomms5494 ↗
62. 10.1016/S0022-1759(98)00170-710.1016/S0022-1759(98)00170-7 ↗